LEADER 01146nam0-22003971i-450-
001 990000885530203316
005 20140506085858.0
010   $a1-55584-116-3
035   $a0088553
035   $aUSA010088553
035   $a(ALEPH)000088553USA01
035   $a0088553
100   $a20020118-1989----kma0ita00103--ba
101 0 $aeng
102   $aUS
105   $a||||||||001yy
200 1 $a<<An>> invisible spectator$ea biography of Paul Bowles$fChristopher Sawyer-Lauçanno
210   $aNew York$cWeidenfield & Nicolson$dcopyr. 1989
215   $aXV, 501 p.$d24 cm
410  0$12001
454  1$12001
461  1$1001-------$12001
676   $a813
700  1$aSAWYER-LAUCANNO,$bChristopher$0746879
801  0$aIT$bsalbc$gISBD
912   $a990000885530203316
951   $aII.2.A.177$b5235 DSLL$cIB
959   $aBK
969   $aDSLL
979   $aPATRY$b90$c20020118$lUSA01$h1305
979   $c20020403$lUSA01$h1733
979   $aPATRY$b90$c20040406$lUSA01$h1701
979   $aDSLL$b90$c20080227$lUSA01$h1603
979   $aMARANO$b90$c20140506$lUSA01$h0858
996   $aInvisible spectator$91491360
997   $aUNISA

LEADER 02736nam  22006135  450 
001 9910917197703321
005 20241209115243.0
010   $a9789819772742
010   $a9819772745
024 7 $a10.1007/978-981-97-7274-2
035   $a(CKB)36959317800041
035   $a(MiAaPQ)EBC31824064
035   $a(Au-PeEL)EBL31824064
035   $a(DE-He213)978-981-97-7274-2
035   $a(OCoLC)1478704403
035   $a(EXLCZ)9936959317800041
100   $a20241209d2024      u|         0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aNew Anti-cancer Drug Development and Evaluation /$fedited by Yongchang Zhang, Nong Yang
205   $a1st ed. 2024.
210  1$aSingapore :$cSpringer Nature Singapore :$cImprint: Springer,$d2024.
215   $a1 online resource (250 pages)
311 08$a9789819772735 
311 08$a9819772737 
327   $aChapter 1. Transformations and Challenges in Cancer Treatment -- Chapter 2. Drug(gable) Targets Discovery -- Chapter 3. Preclinical and Translational Study Design -- Chapter 4. Clinical Trials -- Chapter 5. Small Molecule Compounds -- Chapter 6. Antibodies -- Chapter 7. Cell Guided Drugs -- Chapter 8. Gene Guided Drugs -- Chapter 9. Biosimilar -- Chapter 10. New Insights on Success and Failed Drugs -- Chapter 11. The Road from Laboratory to Patient.
330   $aThis book aims to help researchers to understand the current status of new drug development in China and major events experienced in the development of new drugs. It also helps clinicians and basic research scientists to grasp the types, indications, and adverse reactions of common new drugs; clarifies key events experienced during the launch of new drugs; and discusses future perspectives of clinical medicine development. This book is also beneficial to clinicians by helping them to better become physician scientists.
606   $aPharmacology
606   $aMedical sciences
606   $aDrug development
606   $aClinical medicine$xResearch
606   $aPharmacology
606   $aPreclinical Research
606   $aClinical Research
615  0$aPharmacology.
615  0$aMedical sciences.
615  0$aDrug development.
615  0$aClinical medicine$xResearch.
615 14$aPharmacology.
615 24$aPreclinical Research.
615 24$aClinical Research.
676   $a615
700   $aZhang$b Yongchang$01779168
701   $aYang$b Nong$01779169
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910917197703321
996   $aNew Anti-Cancer Drug Development and Evaluation$94302419
997   $aUNINA